A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Intrapatient dose escalation of biweekly FTD/TPI plus BEV was feasible and well tolerated and may enhance the efficacy of refractory mCRC treatment. Nonetheless, further studies are warranted to validate this individualized dosing strategy.
Authors
- H. Taniguchi
- Hiroyuki Takeda (ORCID: https://orcid.org/0000-0002-2847-7105)
- Tadashi Matsuda (ORCID: https://orcid.org/0000-0003-0973-1478)
- Naoya Akazawa (ORCID: https://orcid.org/0000-0002-2891-6550)
- Y. Sunakawa
- C. Inagaki
- A. Makiyama
- K. Muro
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Yuta Okumura
- Kohei Arimizu
- S. Mitani
- T. Kudo
- Keita Mori (ORCID: https://orcid.org/0000-0002-5473-1488)
- Chiho Kudo (ORCID: https://orcid.org/0000-0002-1689-3566)
- Satoshi Yuki (ORCID: https://orcid.org/0000-0002-2039-3062)
Institutions
- Toho University (JP)
- St. Marianna University School of Medicine (JP)
- Shizuoka Cancer Center (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Kindai University Hospital (JP)
- Toho University Omori Medical Center (JP)
- Gifu University Hospital (JP)
- Sendai Medical Center (JP)
- Aichi Cancer Center (JP)
- Hokkaido University Hospital (JP)
- Osaka International Cancer Institute (JP)
- Kindai University (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105571
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Daiichi-Sankyo